- Home
- MCR vs MNPR Comparison
MCR vs MNPR Comparison
Compare MCR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCR
- MNPR
- Stock Information
- Founded
- MCR 1989
- MNPR 2014
- Country
- MCR United States
- MNPR United States
- Employees
- MCR N/A
- MNPR N/A
- Industry
- MCR Trusts Except Educational Religious and Charitable
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- MCR Finance
- MNPR Health Care
- Exchange
- MCR Nasdaq
- MNPR Nasdaq
- Market Cap
- MCR 250.1M
- MNPR 249.5M
- IPO Year
- MCR N/A
- MNPR 2019
- Fundamental
- Price
- MCR $6.26
- MNPR $33.82
- Analyst Decision
- MCR
- MNPR Strong Buy
- Analyst Count
- MCR 0
- MNPR 5
- Target Price
- MCR N/A
- MNPR $59.50
- AVG Volume (30 Days)
- MCR 66.7K
- MNPR 18.3K
- Earning Date
- MCR 01-01-0001
- MNPR 05-13-2025
- Dividend Yield
- MCR 8.52%
- MNPR N/A
- EPS Growth
- MCR N/A
- MNPR N/A
- EPS
- MCR 0.38
- MNPR N/A
- Revenue
- MCR N/A
- MNPR N/A
- Revenue This Year
- MCR N/A
- MNPR N/A
- Revenue Next Year
- MCR N/A
- MNPR N/A
- P/E Ratio
- MCR $16.61
- MNPR N/A
- Revenue Growth
- MCR N/A
- MNPR N/A
- 52 Week Low
- MCR $5.63
- MNPR $1.72
- 52 Week High
- MCR $6.70
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- MCR 57.62
- MNPR 40.83
- Support Level
- MCR $6.17
- MNPR $37.81
- Resistance Level
- MCR $6.36
- MNPR $44.40
- Average True Range (ATR)
- MCR 0.06
- MNPR 3.89
- MACD
- MCR 0.02
- MNPR -1.03
- Stochastic Oscillator
- MCR 65.00
- MNPR 3.62
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.